 
From: http://www.aclu.org/blog/womens-rights-free-speech/remembering-real-purpose-patents
By 
James Evans,  Bryson Distinguished Professor of Genetics and Medicine, University of  North Carolina - Chapel Hill School of Medicine
As we head toward Supreme Court review of whether genes can be  patented, it is important to remember a simple, but often-overlooked  fact about patents and the protection of intellectual property. The  intent of the patent system is to achieve a social good—not to stimulate  commerce.
Patents are enshrined in the U.S. Constitution for a single purpose:  "to promote the progress of science and useful arts." It is indeed the  case that one 
mechanism by which such progress is secured,  derives—in part—from appealing to the desire for profit (Lincoln's  famous "fuel of interest" added to the "fire of genius"). But it should  not be forgotten that the express purpose of granting patents is to  advance a social good: the free dissemination of information that then  leads to progress.
When it comes to gene patents, that social good has been clearly damaged. As documented in the 
report  of the Secretary's Advisory Committee on Genetics, Health and Society,  the interest of patients and the public has been hurt by the exclusivity  generated through gene patents.
Consider what has happened time and time again when gene patents and  exclusive licenses have been enforced (e.g., genes connected to  hereditary breast cancer or spinal cerebellar ataxia)—numerous labs that  had no trouble developing diagnostic tests were shut down, leaving  patients and providers with only a single (often substandard and  unaffordable) option for testing. Yet, in parallel situations where  exclusive patent rights were not a factor (e.g., genes connected to  hereditary predisposition to colon cancer or Huntington disease),  numerous labs thrive—and importantly, compete on the basis of service,  quality and innovation, benefitting all.
The protection of intellectual property is critical to the progress  our society has made in fields ranging from the arts to physics. But too  much protection is just as damaging to society as too little.
If the Supreme Court overturns the current status quo this summer and  renders genes ineligible for patenting, a few will suffer—namely the  handful of companies who have sought exclusivity over genes and other  naturally occurring substances, simply to promote a business model. But  many more will benefit. In the spirit of our founders' original intent,  progress in biomedical research will be enabled; patients and their  providers will have a choice as to where to obtain diagnostic studies  and the resulting competition will continue to drive quality and  innovation, benefitting us all. 
Read more!